Community oncology practices now treat more than half of cancer patients in the United States, positioning them as primary providers of cancer care. A recent McKesson report highlights the challenges these centers face in adopting clinical innovations and adapting to changing patient demographics.
The Advancing Community Oncology Report, based on a national survey and insights gathered at McKesson’s Accelerate conference, identifies opportunities for biopharmaceutical companies to collaborate with community oncology practices to enhance patient outcomes.
Jason Hammonds, president of oncology and multispecialty at McKesson, emphasized that cancer care in the U.S. is at a critical juncture. He noted that the evolving landscape presents both challenges and opportunities for community providers and biopharma firms striving to improve access to advanced treatments.
The report outlines important considerations for pharmaceutical access professionals seeking to support community oncology practices and patients effectively.
Leave a Reply